Angiogenesis and ovarian function

Journal fur Fertilitat und Reproduktion

Volumn 15, Issue 4, 2005, Pages 7-15

  Douglas, N C ^c   Nakhuda, G S ^c   Sauer, M V ^c   Zimmermann, R C ^a,b  

^a Department of Orthopaedic Surgery   (United States)

^b Columbia University ^*  (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; CONTRACEPTION; CORPUS LUTEUM; ENDOMETRIOSIS; HUMAN; MORPHOGENESIS; NONHUMAN; OVARY CANCER; OVARY FOLLICLE DEVELOPMENT; OVARY FUNCTION; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PREGNANCY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 31644436326     PISSN: 1019066X     EISSN: 16809416     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
2. Folkman J, Klagsbrun M. Vascular physiology. A family of angiogenic peptides. Nature 1987; 329: 671-2.
3. Klagsbrun M, D'Amore PA. Regulators of angiogenesis. Annu Rev Physiol 1991; 53: 217-39.
4. Mignatti P, Rifkin DB. Plasminogen activators and matrix metallo-proteinases in angiogenesis. Enzyme Protein 1996; 49: 117-37.
5. Bischoff J. Cell adhesion and angiogenesis. J Clin Invest 1997; 100: S37-9.
6. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-39.
7. Presta M, Moscatelli D, Joseph-Silverstein J, Rifkin DB. Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration. Mol Cell Biol 1986; 6: 4060-6.
8. Suri C et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87: 1171-80.
9. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999; 18: 5356-62.
10. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
11. Modlich U, Kaup FJ, Augustin HG. Cyclic angiogenesis and blood vessel regression in the ovary: blood vessel regression during luteolysis involves endothelial cell detachment and vessel occlusion. Lab Invest 1996; 74: 771-80.
12. Gordon JD, Shifren JL, Foulk RA, Taylor RN, Jaffe RB. Angiogenesis in the human female reproductive tract. Obstet Gynecol Surv 1995; 50: 688-97.
13. Abulafia O, Sherer DM. Angiogenesis of the endometrium. Obstet Gynecol 1999; 94: 148-53.
14. Rabbani ML, Rogers PA. Role of vascular endothelial growth factor in endometrial vascular events before implantation in rats. Reproduction 2001; 122: 85-90.
15. Speroff L, Fritz M. Clinical gynecologic endocrinology and infertility. Lippincott Williams and Wilkins, New York, 2005.
16. McGee EA, Hsueh AJ. Initial and cyclic recruitment of ovarian follicles. Endocr Rev 2000; 21: 200-14.
17. Gougeon A. Dynamics of follicular growth in the human: a model from preliminary results. Hum Reprod 1986; 1: 81-7.
18. Zeleznik AJ, Schuler HM, Reichert LE Jr. Gonadotropin-binding sites in the rhesus monkey ovary: role of the vasculature in the selective distribution of human chorionic gonadotropin to the preovulatory follicle. Endocrinology 1981; 109: 356-62.
19. Wulff C, Dickson SE, Duncan WC, Fraser HM. Angiogenesis in the human corpus luteum: simulated early pregnancy by HCG treatment is associated with both angiogenesis and vessel stabilization. Hum Reprod 2001; 16: 2515-24.
20. Wiltbank MC, Dysko RC, Gallagher KP, Keyes PL. Relationship between blood flow and steroidogenesis in the rabbit corpus luteum. J Reprod Fertil 1988; 84: 513-20.
21. Goede V, Schmidt T, Kimmina S, Kozian D, Augustin HG. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab Invest 1998; 78: 1385-94.
22. Farin CE, Moeller CL, Sawyer HR, Gamboni F, Niswender GD. Morphometric analysis of cell types in the ovine corpus luteum throughout the estrous cycle. Biol Reprod 1986; 35: 1299-308.
23. Lei ZM, Chegini N, Rao CV. Quantitative cell composition of human and bovine corpora lutea from various reproductive states. Biol Reprod 1991; 44: 1148-56.
24. Reynolds LP, Killilea SD, Redmer DA. Angiogenesis in the female reproductive system. Faseb J 1992; 6: 886-92.
25. Augustin HG, Braun K, Telemenakis I, Modlich U, Kuhn W. Ovarian angiogenesis. Phenotypic characterization of endothelial cells in a physiological model of blood vessel growth and regression. Am J Pathol 1995; 147; 339-51.
26. Reynolds LP, Redmer DA. Expression of the angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, in the ovary. J Anim Sci 1998; 76: 1671-81.
27. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66-70.
28. Fong GH, Zhang L, Bryce DM, Peng J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development 1999; 126: 3015-25.
29. Karkkainen MJ, Makinen T, Alitalo K. Lymphatic endothelium: a new frontier of metastasis research. Nat Cell Biol 2002; 4: E2-5.
30. Carmeliet P et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435-9.
31. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
32. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611.
33. Otani N et al. The vascular endothelial growth factor/fms-like tyrosine kinase system in human ovary during the menstrual cycle and early pregnancy. J Clin Endocrinol Metab 1999; 84: 3845-51.
34. Yamamoto S et al. Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary. Gynecol Endocrinol 1997; 11: 371-81.
35. Gordon JD, Mesiano S, Zaloudek CJ, Jaffe RB. Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation. J Clin Endocrinol Metab 1996; 81: 353-9.
36. Zimmermann RC, Xiao E, Bohlen P, Ferin M. Administration of antivascular endothelial growth factor receptor 2 antibody in the early follicular phase delays follicular selection and development in the rhesus monkey. Endocrinology 2002; 143: 2496-502.
37. Zimmermann RC et al. Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey. J Clin Endocrinol Metab 2001; 86: 768-72.
38. Fraser HM, Wilson H, Rudge JS, Wiegand SJ. Single injections of vascular endothelial growth factor trap block ovulation in the macaque and produce a prolonged, dose-related suppression of ovarian function. J Clin Endocrinol Metab 2005; 90: 1114-22.
39. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-95.
40. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
41. Wulff C, Wiegand SJ, Saunders PT, Scobie GA, Fraser HM. Angiogenesis during follicular development in the primate and its inhibition by treatment with truncated Flt-1-Fc (vascular endothelial growth factor Trap(A40)). Endocrinology 2001; 142: 3244-54.
42. Wulff C, Wilson H, Wiegand SJ, Rudge JS, Fraser HM. Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. Endocrinology 2002; 143: 2797-807.
43. Zimmermann RC et al. Vascular endothelial growth factor receptor 2-mediated angiogenesis is essential for gonadotropin-dependent follicle development. J Clin Invest 2003; 112: 659-69.
44. Halpin DM, Charlton HM. Effects of short-term injection of gonadotrophins on ovarian follicle development in hypogonadal (hpg) mice. J Reprod Fertil 1988; 82: 393-400.
45. Wang XN, Greenwald GS. Hypophysectomy of the cyclic mouse. I. Effects on folliculogenesis, oocyte growth, and follicle-stimulating hormone and human chorionic gonadotropin receptors. Biol Reprod 1993; 48: 585-94.
46. Wang XN, Greenwald GS. Hypophysectomy of the cyclic mouse. II. Effects of follicle-stimulating hormone (FSH) and luteinizing hormone on folliculogenesis, FSH and human chorionic gonadotropin receptors, and steroidogenesis. Biol Reprod 1993; 48: 595-605.
47. Nakhuda GS et al. Inhibition of the vascular endothelial cell (VE)-specific adhesion molecule VE-cadherin blocks gonadotropin-dependent folliculogenesis and corpus luteum formation and angiogenesis. Endocrinology 2005; 146: 1053-9.
48. LeCouter J et al. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 2001; 412: 877-84.
49. LeCouter J et al. Mouse endocrine gland-derived vascular endothelial growth factor: a distinct expression pattern from its human ortholog suggests different roles as a regulator of organ-specific angiogenesis. Endocrinology 2003; 144: 2606-16.
50. Rodger FE, Young FM, Fraser HM, Illingworth PJ. Endothelial cell proliferation follows the mid-cycle luteinizing hormone surge, but not human chorionic gonadotrophin rescue, in the human corpus luteum. Hum Reprod 1997; 12: 1723-9.
51. Fraser HM, Lunn SF. Angiogenesis and its control in the female reproductive system. Br Med Bull 2000; 56: 787-97.
52. Fraser HM et al. Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor. Endocrinology 2000; 141: 995-1000.
53. Dickson SE, Bicknell R, Fraser HM. Mid-luteal angiogenesis and function in the primate is dependent on vascular endothelial growth factor. J Endocrinol 2001; 168: 409-16.
54. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998; 125: 1591-8.
55. Wulff C et al. Luteal angiogenesis: prevention and intervention by treatment with vascular endothelial growth factor trap(A40). J Clin Endocrinol Metab 2001; 86: 3377-86.
56. Ferrara N et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998; 4: 336-40.
57. Geva E, Jaffe RB. Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril 2000; 74: 429-38.
58. Zimmermann RC, Hartman T, Bohlen P, Sauer MV, Kitajewski J. Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in corpora lutea. Microvasc Res 2001; 62: 15-25.
59. Pauli SA et al. The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent. Endocrinology 2005; 146: 1301-11.
60. Rowe AJ, Morris KD, Bicknell R, Fraser HM. Angiogenesis in the corpus luteum of early pregnancy in the marmoset and the effects of vascular endothelial growth factor immunoneutralization on establishment of pregnancy. Biol Reprod 2002; 67: 1180-8.
61. Basini G, Baratta M, Ponderato N, Bussolati S, Tamanini C. Is nitric oxide an autocrine modulator of bovine granulosa cell function? Reprod Fertil Dev 1998; 10: 471-8.
62. Ryan NK, Van der Hoek KH, Robertson SA, Norman RJ. Leptin and leptin receptor expression in the rat ovary. Endocrinology 2003; 144: 5006-13.
63. Yamakawa M et al. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ Res 2003; 93: 664-73.
64. Yancopoulos GD et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.
65. Neulen J et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 1995; 80: 1967-71.
66. Gomez R, Simon C, Remohi J, Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 2002; 143: 4339-48.
67. Agrawal R et al. Serum vascular endothelial growth factor concentrations and ovarian stromal blood flow are increased in women with polycystic ovaries. Hum Reprod 1998; 13: 651-5.
68. Agrawal R, Jacobs H, Payne N, Conway G. Concentration of vascular endothelial growth factor released by cultured human luteinized granulosa cells is higher in women with polycystic ovaries than in women with normal ovaries. Fertil Steril 2002; 78: 1164-9.
69. Hazelton D, Nicosia RF, Nicosia SV. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin Cancer Res 1999; 5: 823-9.
70. Monk BJ, Choi DC, Pugmire G, Burger R. A. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2005; 96: 902-5.
71. Basu S et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001; 7: 569-74.
72. McClure N et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994; 344: 235-6.
73. Levin ER et al. Role of vascular endothelial cell growth factor in Ovarian Hyperstimulation Syndrome. J Clin Invest 1998; 102: 1978-85.
74. Mathur R, Hayman G, Bansal A, Jenkins J. Serum vascular endothelial growth factor levels are poorly predictive of subsequent ovarian hyperstimulation syndrome in highly responsive women undergoing assisted conception. Fertil Steril 2002; 78: 1154-8.
75. McElhinney B, Ardill J, Caldwell C, McClure N. Preventing ovarian hyperstimulation syndrome by inhibiting the effects of vascular endothelial growth factor. J Reprod Med 2003; 48: 243-6.
76. Abd El Aal DE, Mohamed SA, Amine AF, Meki AR. Vascular endothelial growth factor and insulin-like growth factor-1 in polycystic ovary syndrome and their relation to ovarian blood flow. Eur J Obstet Gynecol Reprod Biol 2005; 118: 219-24.
77. Ferrara N et al. Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries. Am J Pathol 2003; 162: 1881-93.
78. Takehara M et al. Vascular endothelial growth factor A and C gene expression in endometriosis. Hum Pathol 2004; 35: 1369-75.
79. Nap AW et al. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab 2004; 89: 1089-95.
80. Maisonpierre PC et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277: 55-60.